Suppr超能文献

利奈唑胺致血小板减少症的群体药动学和药效学的外部评估:已发表模型在不同住院患者中的可转移性。

External Evaluation of Population Pharmacokinetics and Pharmacodynamics in Linezolid-Induced Thrombocytopenia: The Transferability of Published Models to Different Hospitalized Patients.

机构信息

Department of Medical Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama.

Center for Pharmacist Education, School of Pharmacy, Nihon University, Funabashi, Chiba.

出版信息

Ther Drug Monit. 2021 Apr 1;43(2):271-278. doi: 10.1097/FTD.0000000000000816.

Abstract

BACKGROUND

The objective of this study was to perform an external evaluation of published linezolid population pharmacokinetic and pharmacodynamic models, to evaluate the predictive performance using an independent data set. Another aim was to offer an elegant environment for display and simulation of both the concentration and platelet count after linezolid administration.

METHODS

We performed a systematic literature search in PubMed for all studies evaluating the population pharmacokinetic and pharmacodynamic parameters of linezolid in patients and selected the models to be used for the external validation. The bias of predictions was visually evaluated by plotting prediction errors (PEs) and relative PEs. The precision of prediction was evaluated by calculating the mean absolute error (MAE), root mean squared error (RMSE), and mean relative error (MRE).

RESULTS

Three articles (models A, B, and C) provided linezolid-induced platelet dynamic models using population pharmacokinetic and pharmacodynamic modeling approaches. The PE and relative PE of both linezolid concentrations and platelet counts for models A and C showed similar predictive distributions. With respect to the prediction accuracy of total linezolid concentration, the MAE, RMSE, and MRE of population prediction values for model C was the smallest. The comparison of the MAE, RMSE, and MRE of patient-individual prediction values for the 3 pharmacodynamic models revealed no large differences.

CONCLUSIONS

We confirmed the transferability of published population pharmacokinetic and pharmacodynamic models and showed that they were suitable for extrapolation to other hospitals and/or patients. This study also introduced application software based on model C for the therapeutic drug monitoring of linezolid.

摘要

背景

本研究旨在对已发表的利奈唑胺群体药代动力学和药效学模型进行外部评估,使用独立数据集评估其预测性能。另一个目的是提供一个优雅的环境,用于显示和模拟利奈唑胺给药后血药浓度和血小板计数。

方法

我们在 PubMed 中进行了一项系统性文献检索,以评估所有评价利奈唑胺在患者中群体药代动力学和药效学参数的研究,并选择用于外部验证的模型。通过绘制预测误差 (PE) 和相对 PE 来直观评估预测偏差。通过计算平均绝对误差 (MAE)、均方根误差 (RMSE) 和平均相对误差 (MRE) 来评估预测精度。

结果

三篇文章(模型 A、B 和 C)使用群体药代动力学和药效学建模方法提供了利奈唑胺诱导的血小板动力学模型。模型 A 和 C 的利奈唑胺浓度和血小板计数的 PE 和相对 PE 均显示出相似的预测分布。就总利奈唑胺浓度的预测准确性而言,模型 C 的群体预测值的 MAE、RMSE 和 MRE 最小。对 3 种药效学模型的患者个体预测值的 MAE、RMSE 和 MRE 进行比较,没有发现明显差异。

结论

我们证实了已发表的群体药代动力学和药效学模型的可转移性,并表明它们适合外推到其他医院和/或患者。本研究还介绍了基于模型 C 的利奈唑胺治疗药物监测应用软件。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验